1.74
                                            Edesa Biotech Inc (EDSA) 最新ニュース
Edesa Biotech (EDSA) Receives Reiterated 'Buy' Rating from HC Wa - GuruFocus
Is Edesa Biotech Inc. stock affected by interest rate hikesWeekly Volume Report & Risk Managed Investment Strategies - newser.com
Is Edesa Biotech Inc. still worth holding after the dipPortfolio Gains Report & Community Driven Trade Alerts - newser.com
Has Edesa Biotech Inc. found a price floorWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Best data tools to analyze Edesa Biotech Inc. stock2025 Trading Volume Trends & Expert Curated Trade Setup Alerts - newser.com
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Edesa Biotech, Inc. (EDSA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Edesa Biotech to Participate in Key Industry Conferences - TipRanks
Edesa Biotech Announces Upcoming Conference Schedule - The Manila Times
Edesa Biotech (NASDAQ: EDSA) to attend BIO-Europe Vienna, LSX London in November 2025 - Stock Titan
Favourable Signals For Edesa Biotech: Numerous Insiders Acquired Stock - simplywall.st
Will Edesa Biotech Inc. stock benefit from sector rotationQuarterly Risk Review & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Edesa Biotech Inc a good long term investmentMean Reversion Trades & Affordable Trading Portfolio - earlytimes.in
Edesa Biotech reports positive Phase III results for ARDS treatment - Yahoo
Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial - Investing.com Canada
EDSA’s Market Surge: Time to Jump In? - StocksToTrade
Edesa Biotech (EDSA) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial By Investing.com - Investing.com South Africa
EDSA’s Performance: What’s Driving the Change? - timothysykes.com
Edesa Biotech Reports Positive Phase 3 Results For Paridiprubart In ARDS - Nasdaq
Edesa Biotech reports positive Phase 3 results for ARDS drug candidate - Investing.com Nigeria
Edesa Biotech Announces Positive Phase 3 Study Results - TipRanks
Edesa Biotech Announces Positive Phase 3 Results for ARDS Treatment - TradingView
Edesa Biotech Announces Positive Phase 3 Results for Paridiprubart in Treating Acute Respiratory Distress Syndrome, Showing Significant Reduction in Mortality - Quiver Quantitative
[8-K] Edesa Biotech, Inc. Reports Material Event | EDSA SEC FilingForm 8-K - Stock Titan
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study - GlobeNewswire
Pigmentation Disorders Treatment Market Is Booming Worldwide 2025-2032 |Abbvie Inc., Edesa Biotech, Inc., Amgen - openPR.com
                大文字化:
                 
                  | 
                ボリューム (24 時間):